Response
http://www.100md.com
《美国整骨期刊》
Neuroscience Research of the Berkshires Pittsfield, Mass
The purpose of my March 2005 review article (J Am Osteopath Assoc. 2005; 105:145–158) was to make it clear that, among the acetylcholinesterase inhibitors, there is no single "best" agent for the treatment of patients with Alzheimer disease. In my own practice, I use all three agents to treat patients for this condition.
In my article, I diligently avoided recommending any agent preferentially. In fact, to avoid the appearance of favoritism toward any of the agents mentioned, I intentionally rotated the sequence of the names when all three agents were presented together. This personal preference of mine diverges from traditional editorial practice, which places lists of agents in alphabetical order by default when no specific treatment recommendations are being made as a result of differences in efficacy or tolerability, for example. My preference required specific instructions to my manuscript editor at THE JOURNAL (R.J. Fiala, MA, oral communication, March 2005).
Drs Shah and Krueger accurately report that head-to-head studies for acetylcholinesterase inhibitors were lacking at the time of publication. These data are now available, however. As anticipated, each acetylcholinesterase inhibitor was efficacious. Subsequent researchers have joined me in stating that physicians cannot easily predict which treatment option would be best for any given patient.
References
1. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int Geriatr Psychopharmacol.1998; 2:55 –65.
2. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published correction appears in BMJ. 2001;322:1456]. BMJ. 1999;318:633–638. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgitool=pubmed&pubmedid=10066203. Accessed September 26, 2006.(Jay M. Ellis, DO)
The purpose of my March 2005 review article (J Am Osteopath Assoc. 2005; 105:145–158) was to make it clear that, among the acetylcholinesterase inhibitors, there is no single "best" agent for the treatment of patients with Alzheimer disease. In my own practice, I use all three agents to treat patients for this condition.
In my article, I diligently avoided recommending any agent preferentially. In fact, to avoid the appearance of favoritism toward any of the agents mentioned, I intentionally rotated the sequence of the names when all three agents were presented together. This personal preference of mine diverges from traditional editorial practice, which places lists of agents in alphabetical order by default when no specific treatment recommendations are being made as a result of differences in efficacy or tolerability, for example. My preference required specific instructions to my manuscript editor at THE JOURNAL (R.J. Fiala, MA, oral communication, March 2005).
Drs Shah and Krueger accurately report that head-to-head studies for acetylcholinesterase inhibitors were lacking at the time of publication. These data are now available, however. As anticipated, each acetylcholinesterase inhibitor was efficacious. Subsequent researchers have joined me in stating that physicians cannot easily predict which treatment option would be best for any given patient.
References
1. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int Geriatr Psychopharmacol.1998; 2:55 –65.
2. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial [published correction appears in BMJ. 2001;322:1456]. BMJ. 1999;318:633–638. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgitool=pubmed&pubmedid=10066203. Accessed September 26, 2006.(Jay M. Ellis, DO)